2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.
Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.
This study showed that it is feasible to think outside the box when considering patient recruitment. In this study, researchers used social media and the Internet to recruit patients. In total, Gitlitz says, 44% of patients came through these means.
Researchers greatly exceeded their statistical expectations, Gitlitz says. For patients with lung adenocarcinoma, researchers set a bar close to the Lung Cancer Mutation Consortium and wanted to demonstrate an increase in actionable mutations from 35% to 50%. In actuality, they found actionable mutations in 76% of patients.
<<<